Omalizumab in the therapy of pediatric asthma

Dimitri Poddighe, Ilaria Brambilla, Amelia Licari, Gian Luigi Marseglia

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

BACKGROUND: Eosinophilic asthma is driven by Th2 immune response and is usually characterized by the increase of total serum IgE levels and/or specific IgE that express single or multiple allergen sensitization. In such an immune- pathological background, the anti-IgE therapy, namely omalizumab, found its main clinical utility and recommendation to treat severe asthma.

OBJECTIVE: in this mini-review, we summarized the most relevant immuno-pathological and clinical evidences supporting the use of omalizumab in the therapy of pediatric asthma, Furthermore, we provided the main practical points for such a therapeutic management.

METHOD: Through the binding of serum free IgE, whose binding to its cell receptors is inhibited, omalizumab impairs not only the effector phase if IgE-mediated asthma, but also affect the IgE biology and the related immune response, globally. Here, the history of omalizaumab has been shortly reviewed from its preclinical development to its clinical validation in pediatric asthma. Thus, recent patents regarding anti-IgE therapy has been discussed.

CONCLUSION: Omalizumab significantly improved the clinical management of severe and uncontrolled pediatric asthma; however, pre-treament IgE levels limited the use of omalizumab in some patients and the cost of the therapy is still relevant;moreover, the optimal duration of the treatment with omalizumab in children has yet to be determined. Finally, the recent generation of a mutant IgE-Fc fragment being resistant to omalizumab binding, might open further therapeutic applications.

Original languageEnglish
JournalRecent Patents on Inflammation and Allergy Drug Discovery
DOIs
Publication statusE-pub ahead of print - Apr 30 2018
Externally publishedYes

Fingerprint

Immunoglobulin E
Asthma
Pediatrics
Therapeutics
Immunoglobulin Fc Fragments
Patents
Omalizumab
Serum
Allergens
History
Costs and Cost Analysis

Cite this

Omalizumab in the therapy of pediatric asthma. / Poddighe, Dimitri; Brambilla, Ilaria; Licari, Amelia; Marseglia, Gian Luigi.

In: Recent Patents on Inflammation and Allergy Drug Discovery, 30.04.2018.

Research output: Contribution to journalArticle

@article{fc072a2f13c1470abaf06ae296236c85,
title = "Omalizumab in the therapy of pediatric asthma",
abstract = "BACKGROUND: Eosinophilic asthma is driven by Th2 immune response and is usually characterized by the increase of total serum IgE levels and/or specific IgE that express single or multiple allergen sensitization. In such an immune- pathological background, the anti-IgE therapy, namely omalizumab, found its main clinical utility and recommendation to treat severe asthma.OBJECTIVE: in this mini-review, we summarized the most relevant immuno-pathological and clinical evidences supporting the use of omalizumab in the therapy of pediatric asthma, Furthermore, we provided the main practical points for such a therapeutic management.METHOD: Through the binding of serum free IgE, whose binding to its cell receptors is inhibited, omalizumab impairs not only the effector phase if IgE-mediated asthma, but also affect the IgE biology and the related immune response, globally. Here, the history of omalizaumab has been shortly reviewed from its preclinical development to its clinical validation in pediatric asthma. Thus, recent patents regarding anti-IgE therapy has been discussed.CONCLUSION: Omalizumab significantly improved the clinical management of severe and uncontrolled pediatric asthma; however, pre-treament IgE levels limited the use of omalizumab in some patients and the cost of the therapy is still relevant;moreover, the optimal duration of the treatment with omalizumab in children has yet to be determined. Finally, the recent generation of a mutant IgE-Fc fragment being resistant to omalizumab binding, might open further therapeutic applications.",
author = "Dimitri Poddighe and Ilaria Brambilla and Amelia Licari and Marseglia, {Gian Luigi}",
note = "Copyright{\circledC} Bentham Science Publishers; For any queries, please email at epub@benthamscience.org.",
year = "2018",
month = "4",
day = "30",
doi = "10.2174/1872213X12666180430161351",
language = "English",
journal = "Recent Patents on Inflammation and Allergy Drug Discovery",
issn = "1872-213X",
publisher = "Bentham Science Publishers",

}

TY - JOUR

T1 - Omalizumab in the therapy of pediatric asthma

AU - Poddighe, Dimitri

AU - Brambilla, Ilaria

AU - Licari, Amelia

AU - Marseglia, Gian Luigi

N1 - Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.org.

PY - 2018/4/30

Y1 - 2018/4/30

N2 - BACKGROUND: Eosinophilic asthma is driven by Th2 immune response and is usually characterized by the increase of total serum IgE levels and/or specific IgE that express single or multiple allergen sensitization. In such an immune- pathological background, the anti-IgE therapy, namely omalizumab, found its main clinical utility and recommendation to treat severe asthma.OBJECTIVE: in this mini-review, we summarized the most relevant immuno-pathological and clinical evidences supporting the use of omalizumab in the therapy of pediatric asthma, Furthermore, we provided the main practical points for such a therapeutic management.METHOD: Through the binding of serum free IgE, whose binding to its cell receptors is inhibited, omalizumab impairs not only the effector phase if IgE-mediated asthma, but also affect the IgE biology and the related immune response, globally. Here, the history of omalizaumab has been shortly reviewed from its preclinical development to its clinical validation in pediatric asthma. Thus, recent patents regarding anti-IgE therapy has been discussed.CONCLUSION: Omalizumab significantly improved the clinical management of severe and uncontrolled pediatric asthma; however, pre-treament IgE levels limited the use of omalizumab in some patients and the cost of the therapy is still relevant;moreover, the optimal duration of the treatment with omalizumab in children has yet to be determined. Finally, the recent generation of a mutant IgE-Fc fragment being resistant to omalizumab binding, might open further therapeutic applications.

AB - BACKGROUND: Eosinophilic asthma is driven by Th2 immune response and is usually characterized by the increase of total serum IgE levels and/or specific IgE that express single or multiple allergen sensitization. In such an immune- pathological background, the anti-IgE therapy, namely omalizumab, found its main clinical utility and recommendation to treat severe asthma.OBJECTIVE: in this mini-review, we summarized the most relevant immuno-pathological and clinical evidences supporting the use of omalizumab in the therapy of pediatric asthma, Furthermore, we provided the main practical points for such a therapeutic management.METHOD: Through the binding of serum free IgE, whose binding to its cell receptors is inhibited, omalizumab impairs not only the effector phase if IgE-mediated asthma, but also affect the IgE biology and the related immune response, globally. Here, the history of omalizaumab has been shortly reviewed from its preclinical development to its clinical validation in pediatric asthma. Thus, recent patents regarding anti-IgE therapy has been discussed.CONCLUSION: Omalizumab significantly improved the clinical management of severe and uncontrolled pediatric asthma; however, pre-treament IgE levels limited the use of omalizumab in some patients and the cost of the therapy is still relevant;moreover, the optimal duration of the treatment with omalizumab in children has yet to be determined. Finally, the recent generation of a mutant IgE-Fc fragment being resistant to omalizumab binding, might open further therapeutic applications.

U2 - 10.2174/1872213X12666180430161351

DO - 10.2174/1872213X12666180430161351

M3 - Article

JO - Recent Patents on Inflammation and Allergy Drug Discovery

JF - Recent Patents on Inflammation and Allergy Drug Discovery

SN - 1872-213X

ER -